STXS Stereotaxis

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

What:Stereotaxis first quarter 2025 financial results conference call
  
When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)
  
Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 4794777.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at .
  
Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please .
  

About Stereotaxis

(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit .



Investor Contacts:                                        
David L. Fischel                                        
Chairman and Chief Executive Officer                        
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
  
EN
22/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE

Stereotaxis Announces $12.5 Million Registered Direct Offering of Comm...

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at...

 PRESS RELEASE

First Clinical Results from MAGiC Catheter Study Published in the Jour...

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature s...

 PRESS RELEASE

Stereotaxis Reports 2025 First Quarter Financial Results

Stereotaxis Reports 2025 First Quarter Financial Results ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve started the year with solid execution on key commercial and innovation efforts,” said David Fischel, Chairman and CEO. “This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy.” “Key ...

 PRESS RELEASE

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, ...

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025 ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  ...

 PRESS RELEASE

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System...

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025 GenesisX pairs clinical capability with broad accessibility in surgical robotics ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year’s Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch